Eli Lilly Taps SeqWright to Use Roche NimbleGen and 454 Tools in Psychiatric Diseases Study | GenomeWeb

Eli Lilly and SeqWright will use Roche NimbleGen arrays and Roche 454 Life Sciences sequencers to study several psychiatric diseases by selective genome sequencing, the firms said last week.

Lilly's goal for the project is to identify genetic variants that are potentially associated with a number of unspecified psychiatric illnesses, the firms said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: experts say race is not a sufficient proxy for studying human genetic diversity and more.

Technology Review writes that CRISPR/Cas9 gene editing firm Editas' success may hinge on a patent case.

Researchers unearthed a bioinformatics error in the Science paper reporting the first ancient African genome, and the authors are seeking an erratum.

A boy's cystic fibrosis carrier status was revealed by a teacher to the parents of children with CF who then sought the boy's transfer to another school, leading to a lawsuit.